Patents by Inventor Osamu Moro

Osamu Moro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of predicting spot formation on the skin using spot site-accelerating genes as an indicator thereof and method of screening inhibitors of spot formation on the skin
    Patent number: 8142761
    Abstract: The present invention provides a skin test method for predicting the formation of spots in the skin. This method is characterized by judging skin to be susceptible to spot formation in the case expression of genes consisting of MLSTD1, MOGAT1, FADS2, FADS1, HSD3B1, ELOVL3, BG1, PECR, FABP7, FA2H, HAO2, ALOX15B, PDE6A, LZTS1, SEC14L4, BAMBI, CIDEA, TERE1, GAL, THRSP, INSIG1 or CUTL2 in the epidermis is accelerated, or the expression of genes consisting of RBBP6, MSMB, WIF1, ANKRD12, FLG, SYNE2, SCEL, NKTR or AMBP in the epidermis is decreased as compared with normal expression in the epidermis.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: March 27, 2012
    Assignee: Shiseido Company, Ltd.
    Inventors: Hirofumi Aoki, Jiro Kishimoto, Osamu Moro
  • Method of Predicting Spot Formation on the Skin Using Spot Site-Accelerating Genes as an Indicator Thereof and Method of Screening Inhibitors of Spot Formation on the Skin
    Publication number: 20090123401
    Abstract: The present invention provides a skin test method for predicting the formation of spots in the skin. This method is characterized by judging skin to be susceptible to spot formation in the case expression of genes consisting of MLSTD1, MOGAT1, FADS2, FADS1, HSD3B1, ELOVL3, BG1, PECR, FABP7, FA2H, HAO2, ALOX15B, PDE6A, LZTS1, SEC14L4, BAMBI, CIDEA, TERE1, GAL, THRSP, INSIG1 or CUTL2 in the epidermis is accelerated, or the expression of genes consisting of RBBP6, MSMB, WIF1, ANKRD12, FLG, SYNE2, SCEL, NKTR or AMBP in the epidermis is decreased as compared with normal expression in the epidermis.
    Type: Application
    Filed: April 24, 2007
    Publication date: May 14, 2009
    Inventors: Hirofumi Aoki, Jiro Kishimoto, Osamu Moro
  • Inhibitors
    Publication number: 20070249915
    Abstract: The present invention provides a skin test method for predicting the formation of spots in the skin. This method judges skin to be susceptible to the formation of spots in the case expression in the epidermis of MCP-2 gene, a polynucleotide capable of hybridizing under highly stringent conditions to mouse AK012157 gene, human FLJ21763 gene or rat S74257 gene, or Mcp9, Mcp10, Isg15, Usp18, Oas12, Gbp2, Gtpi, Ifi47, Igtp, Tgtp, Sprr2A, Krt2-6b, Cdk5rap2, Mef2C, Gsta4, Osf2, Tnc, Igfbp6, Ppicap or Mm. 74656 gene, is increased as compared with normal expression in the epidermis.
    Type: Application
    Filed: September 30, 2004
    Publication date: October 25, 2007
    Applicant: Shiseido Company, Ltd.
    Inventors: Hirofumi Aoki, Tatsuhiro Kodama, Kiyotaka Hasegawa, Kentaro Kajiya, Yumiko Ishimatatsu, Masashi Ogou, Seiichi Yoshida, Jiro Kishimoto, Osamu Moro
  • Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
    Patent number: 6462016
    Abstract: There are provided a method to screen agonist or antagonist of the maxadilan receptor participating in vasodilating action, wherein a receptor of maxadilan is used, compounds which specifically bind to the receptor, and a tissue preparation having the receptor. The compounds are variants of maxadilan from the salivary glands of the sand fly.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: October 8, 2002
    Assignees: Shiseido Company, Ltd., The General Hospital Corporation
    Inventors: Kawori Wakita, Osamu Moro, Manami Ohnuma, Ethan A. Lerner, Masahiro Tajima
  • Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
    Patent number: 6017533
    Abstract: This specification relates to the use of peptides having a specific affinity to pituitary adenylate cyclase activating polypeptide (PACAP) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M65 acts as an antagonist to PACAP type 1 receptors.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: January 25, 2000
    Assignees: Shiseido Company, Ltd., The General Hospital Corporation
    Inventors: Osamu Moro, Kawori Wakita, Manami Ohnuma, Ethan A. Lerner, Masahiro Tajima
  • Aerosol composition
    Patent number: 5223244
    Abstract: An aerosol composition containing a composite powder and one or more of propane, isobutane, n-butane and a liquefied petroleum gas (i.e., LPG) which is a mixture thereof, a chlorinated hydrocarbon and dimethyl ether.
    Type: Grant
    Filed: December 13, 1990
    Date of Patent: June 29, 1993
    Assignee: Shiseido Company, Ltd.
    Inventors: Osamu Moro, Toshihiko Nakane, Shuya Tamaki, Tsunehiko Iwai
  • Magnesium aluminometasilicate coated composite powder and use thereof
    Patent number: 5182103
    Abstract: A magnesium aluminometasilicate coated composite powder which comprises magnesium aluminometasilicate, or magnesium aluminometasilicate and at least one other powder coated on a surface of a core powder and which is usable in, for example, a skin treatment agent, decodorant, and oral composition.
    Type: Grant
    Filed: June 6, 1989
    Date of Patent: January 26, 1993
    Assignee: Shiseido Company, Ltd.
    Inventors: Toshihiko Nakane, Masumi Koishi, Hiroshi Fukui, Yutaka Okunuki, Yoshio Yahata, Shigenori Kumagai, Hiroyuki Yokoyama, Eiichiro Yagi, Minoru Fukuda, Tadao Ohta, Fujihiro Kanda, Kazuhisa Ohno, Toshihide Ebisawa, Tomiyuki Nanba, Susumu Takada, Masato Hatao, Masaru Suetsugu, Toshihiro Tanaka, Osamu Moro